aibioNMTC NEUROONE MEDICAL TECHNOLOGIES Corp
NEUROONE MEDICAL TECHNOLOGIES (NMTC) news
NEUROONE MEDICAL TECHNOLOGIES Corp is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NMTC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest NEUROONE MEDICAL TECHNOLOGIES news
We have not published a story on NEUROONE MEDICAL TECHNOLOGIES yet. When there is news, it will appear here.
NEUROONE MEDICAL TECHNOLOGIES annual financials
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Revenue | $9.1 million | $3.5 million |
| Research and development | $5.0 million | $5.1 million |
| Net income (loss) | -$3.6 million | -$12.3 million |
| Cash from operations | -$2.8 million | -$11.0 million |
| Cash and equivalents | $6.6 million | $1.5 million |
Questions about NEUROONE MEDICAL TECHNOLOGIES
What is the ticker symbol of NEUROONE MEDICAL TECHNOLOGIES?
NEUROONE MEDICAL TECHNOLOGIES Corp trades under the ticker NMTC on NASDAQ.
Where is NEUROONE MEDICAL TECHNOLOGIES listed?
NEUROONE MEDICAL TECHNOLOGIES Corp is listed on NASDAQ.
Which country or territory is NEUROONE MEDICAL TECHNOLOGIES listed under?
Our directory records NEUROONE MEDICAL TECHNOLOGIES Corp under United States.
Does aibio.space cover NEUROONE MEDICAL TECHNOLOGIES?
aibio.space lists NEUROONE MEDICAL TECHNOLOGIES Corp among 2,820 public biotech companies and publishes its news here as stories appear.
What was NEUROONE MEDICAL TECHNOLOGIES's revenue last year?
$9.1 million for the fiscal year ended Sep 30, 2025, as reported to the SEC.
Is NEUROONE MEDICAL TECHNOLOGIES profitable?
NEUROONE MEDICAL TECHNOLOGIES Corp reported a net loss of $3.6 million for the fiscal year ended Sep 30, 2025, and used $2.8 million of cash in operations, per its annual report to the SEC.
How much does NEUROONE MEDICAL TECHNOLOGIES spend on research and development?
$5.0 million in the fiscal year ended Sep 30, 2025, per its annual report.
How much cash does NEUROONE MEDICAL TECHNOLOGIES have?
$2.0 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: NEUROONE MEDICAL TECHNOLOGIES
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,8.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
- Legal
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Stock chart
Listing details
- Company
- NEUROONE MEDICAL TECHNOLOGIES Corp
- Ticker
- NMTC
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction